http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Baxter to Host Annual Meeting of Stockholders in Virtual Format
-
Baxter to Present at Raymond James 45th Annual Institutional Investors Conference
-
Baxter Declares Quarterly Dividend
-
Baxter Reports Fourth-Quarter and Full-Year 2023 Results
-
Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors
-
Nuwellis (NUWE) Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
-
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
-
Baxter Advances First Intravenous (IV) Bag Recycling Pilot for U.S. Hospitals
-
Baxter to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Baxter Publishes Task Force on Climate-Related Financial Disclosures (TCFD) Report and Is Named to Dow Jones Sustainability Index North America
-
Nuwellis (NUWE) Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
-
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
-
Baxter Declares Quarterly Dividend
-
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Baxter Highlights New Data at Kidney Week Indicating Sharesource Is Associated With a 77% Lower Risk of Home Dialysis Technique Failure
-
Baxter Reports Third-Quarter 2023 Results
-
Nuwellis Announces Board of Directors Transition
-
Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
-
Baxter Launches Digital Image Capture Capability for PanOptic Plus Ophthalmoscope
-
Baxter (BAX) Appoints Joel Grade Chief Financial Officer
-
Baxter Appoints Joel Grade Chief Financial Officer
-
Baxter to Host Third-Quarter 2023 Financial Results Conference Call for Investors
-
ROSEN, A LEADING LAW FIRM, Encourages Baxter International Inc. Investors With Losses to Secure Counsel Before Important September 11 Deadline in Securities Class Action – BAX
-
Baxter to Present at Morgan Stanley 21st Annual Global Healthcare Conference
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Baxter International Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BAX
-
Advent International and Warburg Pincus Name Franco Negron CEO of BioPharma Solutions Following its Proposed Divestiture from Baxter
-
Baxter to Present at 2023 Wells Fargo Healthcare Conference
-
Baxter (BAX) Announces Board Changes
-
Baxter Announces Updates to Its Board of Directors
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BAX
-
Baxter Reports Second-Quarter 2023 Results
-
Baxter (BAX) Picks Vantive as the Name of Proposed Kidney Care Spinoff
-
Baxter Announces Vantive as the Name of Proposed Kidney Care Spinoff
-
Baxter Launches PERCLOT Absorbable Hemostatic Powder
-
Baxter Declares Quarterly Dividend
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Baxter International Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BAX
-
Baxter (BAX) Appoints William Ampofo to Its Board
-
Baxter Appoints William Ampofo to Its Board
-
Baxter Launches Progressa+ Next Gen ICU Bed to Help Address Complex Critical Care Needs
-
Baxter Publishes Annual Corporate Responsibility Report, Reinforcing Longstanding Commitment to Making a Meaningful Difference
-
Nuwellis Inc. Announces Pilot Agreement With DaVita Inc.
-
Baxter to Host Second-Quarter 2023 Financial Results Conference Call for Investors
-
Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference
-
Nuwellis (NUWE) Announces Appointment of Mike McCormick to its Board of Directors
-
Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors
-
Baxter to Present at Jefferies Healthcare Conference
-
Artivion (AORT) Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter (BAX)
-
Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter
-
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Baxter (BAX) Announces CFO Transition, Maintains Outlook